What is Jiangsu Bioperfectus Technologies Co., Ltd.'s (688399.SS) StockRank?

MoatMap's StockRank for Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) is 34/100, with a Sell signal. This is a composite score combining Quality (43), Value (45), and Momentum (37) factor ranks across MoatMap's 19,000+ stock universe.

Does Jiangsu Bioperfectus Technologies Co., Ltd. have an economic moat?

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Jiangsu Bioperfectus Technologies Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Jiangsu Bioperfectus Technologies Co., Ltd. in?

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688399.SS

SELLREMOVE

Jiangsu Bioperfectus Technologies Co., Ltd. · Healthcare · China · $658M · Avg Vol: $13M/d

StockRank

P/E (TTM)

—

ROE

-1.1%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Jiangsu Bioperfectus is an in-vitro diagnostics player facing post-pandemic demand normalization and severe domestic price compression from volume-based procurement.

COMPANY DESCRIPTION

Jiangsu Bioperfectus Technologies Co., Ltd. develops and manufactures in-vitro diagnostic (IVD) reagents and instruments, specializing in molecular diagnostics for infectious diseases. The company has established a strong market position in China's public health and clinical testing sectors with its comprehensive portfolio of PCR test kits and automated nucleic acid extractors. It operates as a highly specialized biotechnology player with a robust R&D pipeline in multiplex PCR and immunodiagnostics.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	818M	60M	52M	50M	-60.6%
EPS	3.11	-0.64	-0.00	-0.07	—
Shares	87M	87M	84M	84M	-3.3%
Debt	15M	26M	36M	56M	53.7%
Equity	558M	503M	480M	433M	-8.1%
Op CF	290M	-17M	22M	4M	-75.1%
Inv CF	-106M	68M	-129M	-29M	—
Fin CF	-99M	8M	-14M	-24M	—

PRICE (1M)-16.5%

SMA 50SMA 200

$7.62

RSI (14)

37.5

52W High

$13.89

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-0.8%43.8

ROE

-1.1%43.5

GP/Assets

5.2%19.1

Op. Margin

-7.5%30.8

FCF/Assets

-0.4%49.3

Piotroski

—55.8

Int. Cover

-2.8x33.6

D/E Ratio

0.18x55.0

Current Ratio

3.33x57.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-103.7x96.5

P/FCF

—N/A

P/B

1.5x66.6

P/S

13.3x22.1

Div Yield

—N/A

Momentum

52W High %

55%29.9

RS 6M

-34%36.2

SMA 50/200

0.87x24.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

65%80.5

FUNDAMENTALS

Market Cap

$658M

P/E (Forward)

—

Gross Margin

56.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688399.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688399.SS	Jiangsu Bioperfectus Technologies Co., Ltd.(you)	$658M	34	SELL
1477.HK	Ocumension Therapeutics	$636M	37	HOLD
603590.SS	Beijing Konruns Pharmaceutical Co.,Ltd.	$810M	33	SELL
301333.SZ	R&G PharmaStudies Co., Ltd.	$724M	38	HOLD
688075.SS	Assure Tech (Hangzhou) Co., Ltd.	$643M	27	SELL
688767.SS	Hangzhou Biotest Biotech Co.,Ltd.	$842M	39	HOLD
301080.SZ	Acrobiosystems Co.,Ltd.	$1.0B	38	HOLD
688488.SS	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	$965M	28	SELL
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
603896.SS	Zhejiang Shouxiangu Pharmaceutical Co., Ltd.	$452M	27	SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) — Stock Score Summary

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) has a MoatMap StockRank of 34/100 based on Quality (43/100), Value (45/100), and Momentum (37/100) factor scores. The current signal is SELL. Jiangsu Bioperfectus is an in-vitro diagnostics player facing post-pandemic demand normalization and severe domestic price compression from volume-based procurement.

Key Financial Metrics

Price	$7.62
Market Cap	$658M
Price/Book	1.48
Return on Equity	-1.1%
Return on Invested Capital	-0.8%
Debt/Equity	17.72
Gross Margin	56.2%
Operating Margin	-7.5%
Revenue Growth	-14.2%
Free Cash Flow	$-326K

Jiangsu Bioperfectus Technologies Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Jiangsu Bioperfectus Technologies Co., Ltd.’s (688399.SS) StockRank?: MoatMap’s StockRank for Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) is 34/100, with a Sell signal. It is a composite of Quality (43), Value (45), and Momentum (37) factor ranks across MoatMap’s 19,000+ stock universe.
Does Jiangsu Bioperfectus Technologies Co., Ltd. have an economic moat?: Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jiangsu Bioperfectus Technologies Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jiangsu Bioperfectus Technologies Co., Ltd. in?: Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).